S3-Leitlinie Empfehlungen zur Therapie von Patienten mit COVID-19 AWMF Register Nummer 113-001LG

Published by Nina Kreuzberger, Nicole Skoetz, Stefan Kluge on Aug 26, 2024

View

Disclaimer

Sponsors

Contact

Abstract

Language

de

PICOS

PICO 10.1

Population
Individuals with COVID-19 and ARDS
Intervention
Prone positioning (> 5 hours)
Comparator
Any position
Outcomes

PICO 10.1

Population
Hospitalised patients with confirmed SARS-CoV-2 infection (WHO 4 to 9)
Intervention
Systemic corticosteroids + Standard of care
Comparator
Standard of Care (plus/minus Placebo)
Outcomes

PICO 10.1

Population
All adult patients (with or without risk factors for COVID-19) with positive PCR test for SARS-CoV-2
Intervention
inhaled corticosteroid
Comparator
placebo and/or standard of care
Outcomes

PICO 10.1

Population
Outpatients with confirmed SARS-CoV-2 infection (at high risk of disease progression)
Intervention
Nirmatrelvir / ritonavir plus standard of care
Comparator
Placebo plus standard of care
Outcomes

PICO 10.2

Population
Hospitalised patients
Intervention
Paxlovid plus standard of care
Comparator
Standard of care alone
Outcomes

PICO 10.2

Population
Hospitalised patients with confirmed SARS-CoV-2 infection (WHO 4 to 9)
Intervention
High-dose dexamethasone (12 mg or higher)
Comparator
Low-dose dexamethasone (6-8 mg)
Outcomes

PICO 10.3

Population
Hospitalised patients with confirmed SARS-CoV-2 infection (WHO 4 to 9)
Intervention
Weight-based dexamethasone (0.2 mg/kg)
Comparator
Low-dose dexamethasone (6-8 mg)
Outcomes

PICO 20.1

Population
Ambulatory managed individuals with a confirmed diagnosis of SARS-CoV-2 infection and mild disease, according to the WHO clinical progression scale (WHO 2 to 3)
Intervention
Remdesivir + Standard of Care
Comparator
Standard of Care (with or without placebo)
Outcomes

PICO 20.1

Population
Hospitalised patients with confirmed SARS-CoV-2 infection (WHO 4 to 9)
Intervention
Tocilizumab + Standard of Care
Comparator
Standard of Care (plus/minus Placebo)
Outcomes

PICO 20.1

Population
Outpatients with confirmed COVID-19 diagnosis
Intervention
Evushield plus standard of care
Comparator
Placebo plus standard of care
Outcomes

PICO 20.1

Population
Hospitalised patients with confirmed SARS-CoV-2 infection and with moderate to severe disease, according to the WHO clinical progression scale (WHO 4 to 9)
Intervention
Intermediate dose anticoagulation
Comparator
Standard thromboprophylaxis (low dose)
Outcomes

PICO 20.1

Population
Ambulatory managed individuals with a confirmed diagnosis of SARS-CoV-2 infection and mild disease, according to the WHO clinical progression scale (WHO 2 to 3)
Intervention
Standard thromboprophylaxis (low dose)
Comparator
No anticoagulation (placebo/SoC)
Outcomes

PICO 20.2

Population
Hospitalised patients with confirmed SARS-CoV-2 infection (WHO 4 to 9)
Intervention
Evushield plus standard of care
Comparator
Placebo plus standard of care
Outcomes

PICO 20.2

Population
Hospitalised patients with confirmed SARS-CoV-2 infection and with moderate to severe disease, according to the WHO clinical progression scale (WHO 4 to 9)
Intervention
Therapeutic dose anticoagulation
Comparator
Standard thromboprophylaxis (low dose/intermediate dose))
Outcomes

PICO 20.2

Population
Ambulatory managed individuals with a confirmed diagnosis of SARS-CoV-2 infection and mild disease, according to the WHO clinical progression scale (WHO 2 to 3)
Intervention
Therapeutic dose anticoagulation
Comparator
No anticoagulation (placebo/SoC)
Outcomes

PICO 20.2

Population
Hospitalised patients with confirmed SARS-CoV-2 infection (WHO 4 to 9)
Intervention
High-dose tocilizumab (8 mg/kg)
Comparator
Low-dose tocilizumab (4 mg/kg)
Outcomes

PICO 20.2

Population
Hospitalised patients with confirmed SARS-CoV-2 infection (WHO 4 to 9)
Intervention
Remdesivir + Standard of Care
Comparator
Standard of Care (with or without placebo)
Outcomes

PICO 20.3

Population
Ambulatory managed individuals with a confirmed diagnosis of SARS-CoV-2 infection and mild disease, according to the WHO clinical progression scale (WHO 2 to 3)
Intervention
Therapeutic dose anticoagulation
Comparator
Standard thromboprophylaxis (low dose)
Outcomes

PICO 20.3

Population
Hospitalised patients with confirmed SARS-CoV-2 infection (WHO 4 to 9)
Intervention
Sotrovimab, 500 mg plus standard of care
Comparator
Placebo plus standard of care
Outcomes

PICO 20.4

Population
Outpatients with confirmed SARS-CoV-2 infection (and at least one risk factor for severe disease)
Intervention
Sotrovimab plus standard of care
Comparator
Placebo plus standard of care
Outcomes

PICO 30.1

Population
Immunocompromised with persistent SARS-CoV-2 infection
Intervention
Combination therapy
Comparator
No therapy
Outcomes

PICO 40.1

Population
Anakinra for the treatment of COVID-19
Intervention
Anakinra
Comparator
standard care with or without placebo or no treatment
Outcomes

PICO 40.1

Population
Post-discharge COVID-19 patients
Intervention
Standard thromboprophylaxis (low dose)
Comparator
No anticoagulation (placebo/SoC)
Outcomes